[go: up one dir, main page]

ECSP22082219A - Derivados de n-(heterociclil y heterociclilalquil)-3-bencilpiridin-2-amina - Google Patents

Derivados de n-(heterociclil y heterociclilalquil)-3-bencilpiridin-2-amina

Info

Publication number
ECSP22082219A
ECSP22082219A ECSENADI202282219A ECDI202282219A ECSP22082219A EC SP22082219 A ECSP22082219 A EC SP22082219A EC SENADI202282219 A ECSENADI202282219 A EC SENADI202282219A EC DI202282219 A ECDI202282219 A EC DI202282219A EC SP22082219 A ECSP22082219 A EC SP22082219A
Authority
EC
Ecuador
Prior art keywords
bencylpyridine
heterocyclylalkyl
heterocyclyl
amine derivatives
compounds
Prior art date
Application number
ECSENADI202282219A
Other languages
English (en)
Inventor
Huikai Sun
Mingnam Tang
Kristin Schleicher
Zacharia Cheruvallath
Jason Green
Original Assignee
Takeda Pharmaceuticals Co
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Takeda Pharmaceuticals Co filed Critical Takeda Pharmaceuticals Co
Publication of ECSP22082219A publication Critical patent/ECSP22082219A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/4965—Non-condensed pyrazines
    • A61K31/497—Non-condensed pyrazines containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/498—Pyrazines or piperazines ortho- and peri-condensed with carbocyclic ring systems, e.g. quinoxaline, phenazine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5375—1,4-Oxazines, e.g. morpholine
    • A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/12—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B2200/00—Indexing scheme relating to specific properties of organic compounds
    • C07B2200/07—Optical isomers

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Pyridine Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

Se describen compuestos de la Fórmula 1 y sales farmacéuticamente aceptables de estos, en donde n, R1, R4, R5, R6, R7, R8, R9, R10, R11, R14, X2, X3 y X12 se definen en la memoria descriptiva. Esta descripción también hace referencia a materiales y métodos para la preparación de compuestos de la Fórmula 1, a composiciones farmacéuticas que los contienen, y a su uso para el tratamiento de enfermedades, trastornos y afecciones asociados con SSTR4.
ECSENADI202282219A 2020-03-31 2022-10-28 Derivados de n-(heterociclil y heterociclilalquil)-3-bencilpiridin-2-amina ECSP22082219A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US202063002623P 2020-03-31 2020-03-31
PCT/US2021/025225 WO2021202775A1 (en) 2020-03-31 2021-03-31 N-(heterocyclyl and heterocyclylalkyl)-3-benzylpyridin-2-amine derivatives as sstr4 agonists

Publications (1)

Publication Number Publication Date
ECSP22082219A true ECSP22082219A (es) 2022-12-30

Family

ID=75660334

Family Applications (1)

Application Number Title Priority Date Filing Date
ECSENADI202282219A ECSP22082219A (es) 2020-03-31 2022-10-28 Derivados de n-(heterociclil y heterociclilalquil)-3-bencilpiridin-2-amina

Country Status (17)

Country Link
US (1) US12428403B2 (es)
EP (1) EP4126849A1 (es)
JP (1) JP7734147B2 (es)
KR (1) KR20220161437A (es)
CN (1) CN115485273B (es)
AR (1) AR121682A1 (es)
AU (1) AU2021249109A1 (es)
BR (1) BR112022019583A2 (es)
CA (1) CA3178347A1 (es)
CL (1) CL2022002692A1 (es)
CO (1) CO2022014111A2 (es)
EC (1) ECSP22082219A (es)
IL (1) IL296602A (es)
MX (1) MX2022012225A (es)
PE (1) PE20230740A1 (es)
TW (1) TW202204342A (es)
WO (1) WO2021202775A1 (es)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AR121682A1 (es) 2020-03-31 2022-06-29 Takeda Pharmaceuticals Co Derivados de n-(heterociclil y heterociclilalquil)-3-bencilpiridin-2-amina como agonistas de sstr4
WO2025247982A1 (en) 2024-05-29 2025-12-04 Grünenthal GmbH Piperazines which act as sstr4 modulators

Family Cites Families (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR0166088B1 (ko) 1990-01-23 1999-01-15 . 수용해도가 증가된 시클로덱스트린 유도체 및 이의 용도
US5376645A (en) 1990-01-23 1994-12-27 University Of Kansas Derivatives of cyclodextrins exhibiting enhanced aqueous solubility and the use thereof
GB9518953D0 (en) 1995-09-15 1995-11-15 Pfizer Ltd Pharmaceutical formulations
GB9711643D0 (en) 1997-06-05 1997-07-30 Janssen Pharmaceutica Nv Glass thermoplastic systems
US6440965B1 (en) 1997-10-15 2002-08-27 Krenitsky Pharmaceuticals, Inc. Substituted pyrimidine derivatives, their preparation and their use in the treatment of neurodegenerative or neurological disorders of the central nervous system
BRPI0611138A2 (pt) 2005-06-02 2010-08-17 Hoffmann La Roche compostos, processo para a manufatura dos mesmos, composições farmacêuticas que os compreendem, método para o tratamento e/ou prevenção de enfermidades que estão associadas com a modulação de receptores de sst subtipo 5 e utilização dos compostos
JO2952B1 (en) 2005-08-03 2016-03-15 جانسين فارماسوتيكا ان. في Quinoline derivatives acting as antibacterial agents
US7674804B2 (en) 2006-06-29 2010-03-09 Hoffmann-La Roche Inc. Pyrimidine and quinazoline derivatives as SST5 modulators
AU2007286344A1 (en) 2006-08-15 2008-02-21 F. Hoffmann-La Roche Ag Phenyl, pyridine and quinoline derivatives
JP5770197B2 (ja) 2009-10-30 2015-08-26 ヤンセン ファーマシューティカ エヌ．ベー． デルタオピオイド受容体調節因子としてのピラジン
US9371282B2 (en) 2013-05-17 2016-06-21 Centrexion Therapeutics Corporation Somatostatin receptor subtype 4 (SSTR4) agonists
EP3596062A4 (en) 2017-03-16 2020-08-26 Crinetics Pharmaceuticals, Inc. SOMATOSTATIN MODULATORS AND THEIR USES
TWI834637B (zh) 2018-03-01 2024-03-11 日商武田藥品工業有限公司 六氫吡啶基-3-(芳氧基)丙醯胺及丙酸酯
AR121683A1 (es) 2020-03-31 2022-06-29 Takeda Pharmaceuticals Co Derivados de n-heteroarilalquil-2-(heterociclil y heterociclilmetil)acetamida como agonistas de sstr4
AR121682A1 (es) 2020-03-31 2022-06-29 Takeda Pharmaceuticals Co Derivados de n-(heterociclil y heterociclilalquil)-3-bencilpiridin-2-amina como agonistas de sstr4

Also Published As

Publication number Publication date
MX2022012225A (es) 2022-10-27
BR112022019583A2 (pt) 2022-12-06
CN115485273A (zh) 2022-12-16
AR121682A1 (es) 2022-06-29
AU2021249109A1 (en) 2022-10-20
TW202204342A (zh) 2022-02-01
CL2022002692A1 (es) 2023-06-16
EP4126849A1 (en) 2023-02-08
CN115485273B (zh) 2024-08-13
KR20220161437A (ko) 2022-12-06
WO2021202775A1 (en) 2021-10-07
US12428403B2 (en) 2025-09-30
CO2022014111A2 (es) 2022-12-30
JP7734147B2 (ja) 2025-09-04
US20230192659A1 (en) 2023-06-22
JP2023520006A (ja) 2023-05-15
IL296602A (en) 2022-11-01
PE20230740A1 (es) 2023-05-03
CA3178347A1 (en) 2021-10-07

Similar Documents

Publication Publication Date Title
CR20220160A (es) Derivados de piridazin-3(2h)-ona fusionados con azol
ECSP23095485A (es) N-(hidroxialquil (hetero)aril) tetrahidrofurano carboxamidas como moduladores de canales de sodio
NI202000078A (es) Compuestos heteroaril tetracíclicos
CL2020002257A1 (es) Piperidinil-3-(ariloxi)propanamidas y propanoatos
CL2022002386A1 (es) Compuestos de amino pirimidina fusionados
ECSP21080966A (es) Derivados de 1,1-dióxido de 3-amino-4h-benzo[e][1,2,4] tiadiazina como inhibidores de mrgx2
ECSP22082217A (es) Derivados de n-heteroarilalquil-2-(heterociclil y heterociclilmetil)acetamida
CL2024001022A1 (es) Moléculas pequeñas para el tratamiento del cáncer
ECSP22082219A (es) Derivados de n-(heterociclil y heterociclilalquil)-3-bencilpiridin-2-amina
AR127050A1 (es) Compuestos espirocíclicos
PA8490601A1 (es) Derivados quinolin-2-ona sustituidos con heteroarilo utiles como agentes anticancerigenos.
CL2022000955A1 (es) Aminas de heteroaril-bifenilo para el tratamiento de enfermedades pd-l1
UY40234A (es) Compuestos heteroarilo para el tratamiento del dolor
CL2021000844A1 (es) Compuestos de indolinona para uso como inhibidores de map4k1
CO2024014680A2 (es) Derivados de n-(pirrolidin-3-il o piperidin-4-il)acetamida
CY1122731T1 (el) Διαμορφωτες υποδοχεα οιστρογονων
CO2024017138A2 (es) Compuestos amido heteroaromáticos útiles en el tratamiento de enfermedades hepáticas
ECSP22091230A (es) Derivados de n-(piperidin-4-il)benzamida de acción luminal
CO2025011205A2 (es) Derivados de 1-amino-4-fenilftalazina útiles para el tratamiento de enfermedades neurodegenerativas
AR054508A1 (es) Compuesto de bencilpiperazina, su uso para preparar un medicamento, procedimientos para la preparacion de dicho compuesto y de compuestos intermediarios, dichos compuestos intermediarios, composicion farmaceutica que lo comprende y procedimiento para prepararla
PA8474401A1 (es) 3-ceto derivados triciclicos de 6-0-metileritromicina
AR134411A1 (es) Compuestos de uracilo